$19.17

-0.03 (-0.16%)

2/9/2010 4:00 PM

BioMarin Pharmaceutical, Inc. (BMRN)

CAPS Rating:

The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating BMRN

Add Stock to Watchlist

What the Community Thinks

Total Members

862 Outperforms

41 Underperforms

All-Stars

222 Outperforms

10 Underperforms

Wall Street

15 Outperforms

1 Underperforms

Members bullish on BMRN are also bullish on:

Members bearish on BMRN are also bearish on:

Ticker Tags

Aggressive Growth (860), Growth (1902), Healthcare (711), Small Cap (1645), Biotechnology (220), Defensive (1457), Rule Breakers Universe (125), Distressed (1597)
Suggest a tag

BioMarin Pharmaceutical, Inc. At A Glance

Current Price:	$19.17
Last Trade Time:	2/9/2010 4:00 PM
Open:	$19.74
Previous Close:	$19.17
Daily Range:	$18.97 - $20.24
52-Week Range:	$9.93 - $21.50
Volume:	2,043,457
Market Cap:	$1.93B
P/E Ratio:	41.67
Compare Our Special Broker Offers!

Stock Trends

BMRN VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for BMRN

Caterpillar: Analysts' Upgrades, Downgrades
2/9/2010 9:33:36 AM -
Upgrades & Downgrades: Monsanto in the Money
2/9/2010 9:00:23 AM -
Aetna: Analysts' Upgrades, Downgrades
2/8/2010 9:29:21 AM -
BioMarin Announces 2010 Guidance
2/4/2010 4:06:00 PM -

More Headlines...

Top Bull Pitch

Recs

1 BioMarin Pharmaceutical, Inc. (BMRN)

Avatar topsecret09 (52.60) Submitted: 10/01/09 11:36 PM

BioMarin has developed and commercialized three products in ten years, a remarkable accomplishment in the biopharmaceutical industry, and a testament to the company’s passion and dedication to patients with serious, unmet medical needs.
BioMarin has three approved products on the market today:
•...More

Replies: 0 | Reply | Permalink

BioMarin has developed and commercialized three products in ten years, a remarkable accomplishment in the biopharmaceutical industry, and a testament to the company’s passion and dedication to patients with serious, unmet medical needs.
BioMarin has three approved products on the market today:
•Kuvan® (sapropterin dihydrochloride) Tablets for PKU
•Naglazyme® (galsulfase) for MPS VI
•Aldurazyme® (laronidase) for MPS I The year 2008 was a very important milestone in BioMarin’s history. We achieved our first profitable full year, with total revenues up 144 percent from 2007 to nearly $300 million, and increased sales across all of our three products. We continue to build an exciting pipeline, with a clinical portfolio featuring PEG-PAL for PKU and GALNS for MPS IVA, and a preclinical lineup that provides hope to many other patients with a variety of other rare diseases.
The year also brought with it the U.S. launch of Kuvan and we have been encouraged by the progress made thus far in a market with unique complexities. We continue to look for new ways to enhance our commercial efforts in this area and we remain very optimistic about the long-term potential of the product.
Other successes throughout the year included several regulatory achievements such as the approval of Naglazyme in Japan and South Korea, and the recent approval of Kuvan secured in the European Union by our partner Merck Serono.
In 2008, BioMarin achieved important milestones that will fuel future growth opportunities in the orphan drug industry. Today, as a fully integrated mid-cap biopharmaceutical company with three products on the market, strong revenues and cash reserves of nearly $560 million, we are confident and well positioned for the long-term. In 2009, we will continue to advance our pipeline and actively pursue valuable business development opportunities to bring increased value to patients, shareholders and employees. Logical buyout candidate In the BIOTECH field,should reward shareholders Into the future... TS

Top Bear Pitch

Recs

1 BioMarin Pharmaceutical, Inc. (BMRN)

Avatar nonothing2 (< 20) Submitted: 8/18/08 5:01 PM

THis company is in a good market because Pharmeceuticals will always be needed, but a PE ration of 659 is simply unsustainable. A PE of above 40 is high, but this companies stock is over 600 times more expensive than its earnings per share. That's bad.

Replies: 1 | Reply | Permalink

CAPS Members

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 106 : 1 2 3 4 5 Next » Jump to page:

Recs 0 (BMRN) JackCaps (< 20) Submitted: 1/21/10 8:11 PM : Start Price: $20.61 BMRN Score: 3.41 A PE of 50 is a bit much for a company whose last 4 quarters had rather flat revenues. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 1 (BMRN) topsecret09 (52.60) Submitted: 10/01/09 11:36 PM : Start Price: $17.70 BMRN Score: 3.20 BioMarin has developed and commercialized three products in ten years, a remarkable accomplishment in the biopharmaceutical industry, and a testament to the company’s passion and dedication to patients with serious, unmet medical needs. BioMarin has three approved products on the market today: •Kuvan® (sapropterin dihydrochloride) Tablets for PKU •Naglazyme® (galsulfase) for MPS VI •Aldurazyme® (laronidase) for MPS I The year 2008 was a very important milestone in BioMarin’s history. We achieved our first profitable full year, with total revenues up 144 percent from 2007 to nearly $300 million, and increased sales across all of our three products. We continue to build an exciting pipeline, with a clinical portfolio featuring PEG-PAL for PKU and GALNS for MPS IVA, and a preclinical lineup that provides hope to many other patients with a variety of other rare diseases. The year also brought with it the U.S. launch of Kuvan and we have been encouraged by the progress made thus far in a market with unique complexities. We continue to look for new ways to enhance our commercial efforts in this area and we remain very optimistic about the long-term potential of the product. Other successes throughout the year included several regulatory achievements such as the approval of Naglazyme in Japan and South Korea, and the recent approval of Kuvan secured in the European Union by our partner Merck Serono. In 2008, BioMarin achieved important milestones that will fuel future growth opportunities in the orphan drug industry. Today, as a fully integrated mid-cap biopharmaceutical company with three products on the market, strong revenues and cash reserves of nearly $560 million, we are confident and well positioned for the long-term. In 2009, we will continue to advance our pipeline and actively pursue valuable business development opportunities to bring increased value to patients, shareholders and employees. Logical buyout candidate In the BIOTECH field,should reward shareholders Into the future... TS Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (BMRN) bestdamstockpkr (72.14) Submitted: 9/11/09 7:26 AM : Start Price: $17.62 BMRN Score: 6.10 i usually don't by based soley on a recommendation without researching it my self, but I did this one. probably a mistake? Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (BMRN) latimerburned (81.51) Submitted: 8/15/09 12:00 PM : Start Price: $15.33 BMRN Score: 16.06 Three approved drugs which are all classified as orphan drugs make this a slightly profitable company. Pipeline is a few years out so look for them to try to make a near term acquisition or be taken out themselves. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (BMRN) clarkinbrazil (82.43) Submitted: 6/03/09 12:06 PM : Start Price: $13.98 BMRN Score: 21.16 With the economy coming back and baby boomers getting older, this company should do very well. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 106 : 1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 16 of 16

picks per page. CHANGE

Top Pick	Member Name	Member Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackRothCapital	80.39	02/09/10		NS	$19.74	-2.89%	+0.08%	-2.97
	TrackCollinsStew	68.03	12/09/09		NS	$17.29	+10.87%	-2.15%	+13.03
	TrackCreditSuiss	93.62	10/30/09		NS	$17.56	+9.17%	+1.93%	+7.24
	TrackJimCramer	< 20	09/16/09		3W	$17.48	+9.67%	+0.70%	-8.97
	TrackFTNEquityCa	65.55	03/12/09		NS	$10.24	+87.21%	+49.78%	+37.43
	TrackLeerinkSwan	92.83	03/12/09		NS	$10.36	+85.04%	+50.25%	+34.79
	TrackCitigroup	85.92	11/21/08		NS	$14.42	+32.94%	+42.64%	-9.70
	TrackWMBlair	69.55	09/12/08		NS	$27.29	-29.75%	-11.01%	-18.75
	TrackSoleil	93.91	08/06/08		NS	$29.06	-34.03%	-13.52%	-20.51
	TrackUBS	87.99	07/25/08		NS	$31.78	-39.68%	-12.28%	-27.40
	TrackJefferies	82.08	11/06/07		NS	$28.25	-32.14%	-25.54%	-6.60
	TrackFerrisBaker	79.44	07/26/07		NS	$18.37	+4.35%	-24.49%	+28.85
	TrackAGEdwards	93.04	02/16/07		NS	$20.30	-5.56%	-21.78%	+16.22
	TrackRodmanRen	< 20	12/19/06		NS	$16.82	+13.97%	-19.53%	+33.50
	TrackBroadpoint.AmTech	76.97	10/10/06		NS	$16.09	+19.14%	-15.77%	+34.91
	TrackRWBaird	87.00	10/02/06		NS	$15.00	+27.80%	-14.76%	+42.56

Results 1 - 16 of 16

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.